3Skinner DB, Wahher BC, Ridder RI-I, et al. Barrett' s esophagus : comparison of benign and malignant cases. Ann Surg, 1983,198554.
4Weston AP, Krmpotich PT, Cherian R, et al. Prospective longterm endoscopic and histological follow- up of short segement Barrett' s esophagus. Am J Gastroenterol, 1997, 92:407.
5SegalF, Kaspary A P, Prolla J C, et al. p53 protein overexpression And p53 mutation analysis in patients with intestinal metaplasia of The cardia and Barrett' s esophagus. Cancer Lett, 2004,210 ( 2 ) : 213-218.
6Deviere JA. Argon plam a coagnlation therapy for ablation of Barrett, s esophagus Gut 2002,551:763-764.
8Kahaleh M, van Laethem JL, Nagy N, et al. Longterm follow up and factors predictive of recurrence in Barretts' esophagus treated by argon plasma coagulation and acid suppression. Endoscopy, 2002,34(12) :950.
9Pereira- Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barretts' esophagus. Am J Gastroenterol, 2000,95 (7) : 1661.
10Axckroy R, Brow N J, Davis MF, er al. Photodynamic therapy for dyspplastixc Barrett' s oesophagua: a prospective, double blind, randomised ,plaxcebo xcontrolled trial. Gut,2000,47:612-617.
6Shaheen NJ,Crosby MA,Bozymski EM,at al.Is there publication bias in the reporting of cancer risk in Barrett's esophagus?Gastroenterology,2000,119:333-338.
7Menges M,Muller M,Zeitz M.Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis,and effect of proton pump inhibitor therapy.Am J Gastroenterol,2001,96:331-337.
8Orlando RC.Mechanisms of epithelial injury and inflammation in gastrointestinal diseases.Rev Gastroenterol Disord,2002,2:S2-S8.
9Souza RF,Shewmake K,Terada LS,et al.Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus.Gastroenterology,2002,122:299-307.
10Buttar NS,Wang KK,Sebo TJ,et al.Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma.Gastroenterology,2001,120:1630-1639.
